{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:24:18Z","timestamp":1789118658256,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-026-02191-3","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:29:08Z","timestamp":1785320948000},"page":"2082-2093","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of a PD-L1 and tumor mutational burden-based predictive model for pathological complete response after neoadjuvant immunotherapy in resectable lung cancer"],"prefix":"10.1007","volume":"48","author":[{"given":"Xiao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"issue":"5","key":"2191_CR1","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.chest.2023.11.042","volume":"165","author":"R Rajaram","year":"2024","unstructured":"Rajaram R, Huang Q, Li RZ, et al. Recurrence-free survival in patients with surgically resected non-small cell lung cancer: a systematic literature review and meta-analysis. Chest. 2024;165(5):1260\u201370. https:\/\/doi.org\/10.1016\/j.chest.2023.11.042.","journal-title":"Chest"},{"key":"2191_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108457","volume":"201","author":"Z Ma","year":"2025","unstructured":"Ma Z, Fu F, Zhang Y, et al. Long-term outcomes of neoadjuvant gefitinib in resectable stage II-IIIA non-small cell lung cancer: a phase II, prospective cohort study. Lung Cancer. 2025;201:108457. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108457.","journal-title":"Lung Cancer"},{"issue":"1","key":"2191_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13311-5","volume":"24","author":"W Zhang","year":"2024","unstructured":"Zhang W, Dai T, Wang D, et al. Efficacy of neoadjuvant PD-1\/PD-L1 inhibitor in resectable NSCLC: a meta-analysis based on randomized controlled trials. BMC Cancer. 2024;24(1):1522. https:\/\/doi.org\/10.1186\/s12885-024-13311-5.","journal-title":"BMC Cancer"},{"key":"2191_CR4","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.2147\/DDDT.S388777","volume":"16","author":"H Xu","year":"2022","unstructured":"Xu H, Wang W, Yin J, et al. Efficacy and safety of the PD-1 inhibitor combined with albumin-bound paclitaxel and nedaplatin in preoperative neoadjuvant therapy of unresectable stage III lung squamous cell carcinoma. Drug Des Devel Ther. 2022;16:4269\u201377. https:\/\/doi.org\/10.2147\/DDDT.S388777.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"2191_CR5","doi-asserted-by":"publisher","first-page":"e241285","DOI":"10.1001\/jamanetworkopen.2024.1285","volume":"7","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Li A, Yu H, et al. Neoadjuvant-adjuvant vs neoadjuvant-only PD-1 and PD-L1 inhibitors for patients with resectable NSCLC: an indirect meta-analysis. JAMA Netw Open. 2024;7(3):e241285. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.1285.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"2191_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/crj.13815","volume":"18","author":"J Gao","year":"2024","unstructured":"Gao J, Nan Y, Liu G, et al. Nomogram for predicting efficacy and prognosis after chemotherapy for advanced NSCLC. Clin Respir J. 2024;18(8):e13815. https:\/\/doi.org\/10.1111\/crj.13815.","journal-title":"Clin Respir J"},{"issue":"3","key":"2191_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00404-020-05908-5","volume":"303","author":"D Liu","year":"2021","unstructured":"Liu D, Zhang X, Zheng T, et al. Optimisation and evaluation of the random forest model in the efficacy prediction of chemoradiotherapy for advanced cervical cancer based on radiomics signature from high-resolution T2 weighted images. Arch Gynecol Obstet. 2021;303(3):811\u201320. https:\/\/doi.org\/10.1007\/s00404-020-05908-5.","journal-title":"Arch Gynecol Obstet"},{"key":"2191_CR8","doi-asserted-by":"publisher","unstructured":"Zhang Y, Wei R, Song G, Yet al. Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies. MAbs. 2024;16(1):2419838. https:\/\/doi.org\/10.1080\/19420862.2024.2419838","DOI":"10.1080\/19420862.2024.2419838"},{"issue":"9","key":"2191_CR9","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jtho.2020.05.019","volume":"15","author":"LM Sholl","year":"2020","unstructured":"Sholl LM, Hirsch FR, Hwang D, et al. The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the international association for the study of lung cancer pathology committee. J Thorac Oncol. 2020;15(9):1409\u201324. https:\/\/doi.org\/10.1016\/j.jtho.2020.05.019.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"2191_CR10","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jtho.2023.03.012","volume":"18","author":"D Sun","year":"2023","unstructured":"Sun D, Liu J, Zhou H, et al. Classification of tumor immune microenvironment according to programmed death-ligand 1 expression and immune infiltration predicts response to immunotherapy plus chemotherapy in advanced patients with NSCLC. J Thorac Oncol. 2023;18(7):869\u201381. https:\/\/doi.org\/10.1016\/j.jtho.2023.03.012.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2191_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s12094-022-02924-6","volume":"25","author":"J Song","year":"2023","unstructured":"Song J, Yan Y, Chen C, Li J, Ding N, Xu N, et al. Tumor mutational burden and efficacy of chemotherapy in lung cancer. Clin Transl Oncol. 2023;25(1):173\u201384. https:\/\/doi.org\/10.1007\/s12094-022-02924-6.","journal-title":"Clin Transl Oncol"},{"key":"2191_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1018288","volume":"13","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, Gao Y, Tan F, et al. Prognostic significance of eighth edition TNM stage criteria in combined small-cell lung cancer. Front Oncol. 2023;13:1018288. https:\/\/doi.org\/10.3389\/fonc.2023.1018288.","journal-title":"Front Oncol"},{"key":"2191_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/CCI-24-00185","volume":"9","author":"M Johnson","year":"2025","unstructured":"Johnson M, Tao P, Burcu M, et al. Creating a proxy for baseline Eastern Cooperative Oncology Group performance status in electronic health records for comparative effectiveness research in advanced non-small cell lung cancer. JCO Clin Cancer Inform. 2025;9:e2400185. https:\/\/doi.org\/10.1200\/CCI-24-00185.","journal-title":"JCO Clin Cancer Inform"},{"issue":"7","key":"2191_CR14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jtho.2024.02.011","volume":"19","author":"R Rami-Porta","year":"2024","unstructured":"Rami-Porta R, Nishimura KK, et al. Members of the IASLC staging and prognostic factors committee and of the advisory boards, and participating institutions. The international association for the study of lung cancer lung cancer staging project: proposals for revision of the tnm stage groups in the forthcoming (Ninth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2024;19(7):1007\u201327. https:\/\/doi.org\/10.1016\/j.jtho.2024.02.011.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"2191_CR15","doi-asserted-by":"publisher","first-page":"e1224","DOI":"10.1093\/oncolo\/oyae098","volume":"29","author":"O Mosalem","year":"2024","unstructured":"Mosalem O, Coston TW, Imperial R, et al. A comprehensive analysis of POLE\/POLD1 genomic alterations in colorectal cancer. Oncologist. 2024;29(9):e1224\u20137. https:\/\/doi.org\/10.1093\/oncolo\/oyae098.","journal-title":"Oncologist"},{"issue":"2","key":"2191_CR16","doi-asserted-by":"publisher","first-page":"408","DOI":"10.21037\/tlcr-24-925","volume":"14","author":"T Ma","year":"2025","unstructured":"Ma T, Yi J, Ge Y, et al. Sleeve lobectomy versus lobectomy after neoadjuvant chemo-immunotherapy for non-small cell lung cancer invading the lobar bronchial orifice: a multicenter retrospective cohort study. Transl Lung Cancer Res. 2025;14(2):408\u201321. https:\/\/doi.org\/10.21037\/tlcr-24-925.","journal-title":"Transl Lung Cancer Res"},{"issue":"7","key":"2191_CR17","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1158\/2159-8290.CD-23-1266","volume":"14","author":"KD Moynihan","year":"2024","unstructured":"Moynihan KD, Kumar MP, Sultan H, et al. IL2 targeted to CD8+ T cells promotes robust effector T-cell responses and potent antitumor immunity. Cancer Discov. 2024;14(7):1206\u201325. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-1266.","journal-title":"Cancer Discov"},{"issue":"1","key":"2191_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-024-02523-5","volume":"19","author":"F Sun","year":"2024","unstructured":"Sun F, Chen Z, Zhou D, et al. Regularity and correlation analysis of regional lymph node metastasis in nonoperative patients with non-small cell lung cancer based on positron emission tomography\/computed tomography images. Radiat Oncol. 2024;19(1):137. https:\/\/doi.org\/10.1186\/s13014-024-02523-5.","journal-title":"Radiat Oncol"},{"issue":"2","key":"2191_CR19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202\u20136. https:\/\/doi.org\/10.1038\/s41588-018-0312-8.","journal-title":"Nat Genet"},{"issue":"1","key":"2191_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-023-00535-z","volume":"12","author":"N Zhang","year":"2024","unstructured":"Zhang N, Yang X, Piao M, et al. Biomarkers and prognostic factors of PD-1\/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma. Biomark Res. 2024;12(1):26. https:\/\/doi.org\/10.1186\/s40364-023-00535-z.","journal-title":"Biomark Res"},{"issue":"5","key":"2191_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008927","volume":"12","author":"Z Han","year":"2024","unstructured":"Han Z, Zhang Z, Yang X, et al. Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer. J Immunother Cancer. 2024;12(5):e008927. https:\/\/doi.org\/10.1136\/jitc-2024-008927.","journal-title":"J Immunother Cancer"},{"key":"2191_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1358306","volume":"15","author":"J Du","year":"2024","unstructured":"Du J, Zhang E, Huang Z. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy. Front Immunol. 2024;15:1358306. https:\/\/doi.org\/10.3389\/fimmu.2024.1358306.","journal-title":"Front Immunol"},{"key":"2191_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.646874","volume":"12","author":"J Jiang","year":"2021","unstructured":"Jiang J, Jin Z, Zhang Y, et al. Robust prediction of immune checkpoint inhibition therapy for non-small cell lung cancer. Front Immunol. 2021;12:646874. https:\/\/doi.org\/10.3389\/fimmu.2021.646874.","journal-title":"Front Immunol"},{"issue":"21","key":"2191_CR24","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2202170.","journal-title":"N Engl J Med"},{"issue":"6","key":"2191_CR25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00109-024-02444-6","volume":"102","author":"A Salminen","year":"2024","unstructured":"Salminen A. The role of the immunosuppressive PD-1\/PD-L1 checkpoint pathway in the aging process and age-related diseases. J Mol Med (Berl). 2024;102(6):733\u201350. https:\/\/doi.org\/10.1007\/s00109-024-02444-6.","journal-title":"J Mol Med (Berl)"},{"key":"2191_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01230-y","volume":"10","author":"Y Mao","year":"2026","unstructured":"Mao Y, Gide TN, Maher NG, et al. Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma. NPJ Precis Oncol. 2026;10:55. https:\/\/doi.org\/10.1038\/s41698-025-01230-y.","journal-title":"NPJ Precis Oncol"},{"issue":"22","key":"2191_CR27","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.26355\/eurrev_202411_36955","volume":"28","author":"YM Zhang","year":"2024","unstructured":"Zhang YM, Fan JK, Wang XY, et al. Study on MKNK2 as a potential prognostic and immunological biomarker in pan-cancer. Eur Rev Med Pharmacol Sci. 2024;28(22):4591\u2013620. https:\/\/doi.org\/10.26355\/eurrev_202411_36955.","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02191-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02191-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02191-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:58:15Z","timestamp":1789117095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02191-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2191"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02191-3","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Henan Provincial Chest Hospital. The requirement for informed consent was waived because of the retrospective nature of the study. This study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}